EP4008317A1 - Solid pharmaceutical formulations of amorphous dapagliflozin - Google Patents

Solid pharmaceutical formulations of amorphous dapagliflozin Download PDF

Info

Publication number
EP4008317A1
EP4008317A1 EP21211906.9A EP21211906A EP4008317A1 EP 4008317 A1 EP4008317 A1 EP 4008317A1 EP 21211906 A EP21211906 A EP 21211906A EP 4008317 A1 EP4008317 A1 EP 4008317A1
Authority
EP
European Patent Office
Prior art keywords
solid pharmaceutical
pharmaceutical formulation
formulation according
tablet
amorphous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21211906.9A
Other languages
German (de)
French (fr)
Inventor
Nur PEHLIVAN AKALIN
Fatih SÜNEL
Aydan OZDEN
Tolga GÜLER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Publication of EP4008317A1 publication Critical patent/EP4008317A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone

Definitions

  • the present invention relates to a solid pharmaceutical formulation comprising amorphous dapagliflozin and at least one pharmaceutically acceptable excipient. Further, the formulations comprising amorphous dapagliflozin are prepared a method which is simple, rapid, cost effective, time-saving and industrially convenient process.
  • Diabetes mellitus is a group of disorders of carbohydrate metabolism in which the action of insulin is diminished or absent through altered secretion, decreased insulin activity or a combination of both factors.
  • Type 1 diabetes occurs because the insulin-producing cells of the pancreas (beta cells) are damaged.
  • Type 1 diabetes the pancreas makes little or no insulin, so sugar cannot get into the body's cells for use as energy.
  • People with Type 1 diabetes must use insulin injections to control their blood glucose.
  • Type 2 diabetes the pancreas makes insulin, but it either doesn't produce enough, or the insulin does not work properly. This diabetes occurs most often in people who are over 40 years old and overweight and type 2 diabetes is the most common type, affecting more than 171 million people worldwide.Type 2 diabetes may sometimes be controlled with a combination of diet, weight management, and exercise. However, treatment also may include oral glucose-lowering medications or insulin injections.
  • Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor (SGLT2).
  • SGLT2 is a carrier responsible for the reabsorption of most of the glucose from the lumen of the renal tubule.
  • SGLT2 is expressed in proximal renal tubules.
  • dapagliflozin reduces the reabsorption of the filtered glucose and lowers the renal threshold for glucose. This improves urinary glucose excretion and blood glucose control.
  • Dapagliflozin also known as (1S)-1,5-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-D-glucitol or (2S,3R,4R,5S,6R)-2-(3-(4-etoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol is represented by the structure of Formula I.
  • Dapagliflozin was first disclosed in patent US 6515117 (2003, Bristol-Myers Squibb ).
  • US2008234366 A1 , US2011064801 A1 and US2012263786 A1 disclose pharmaceutical compositions comprising dapagliflozin or dapagliflozin propylene glycol hydrate and specific excipients in given amounts.
  • WO2008116178 refers to pharmaceutical formulations which include crystalline dapagliflozin propylene glycol hydrate.
  • US2011064801 A1 further discloses pharmaceutical compositions in the form of a stock granulation comprising dapagliflozin propylene glycol hydrate and excipients in given amounts.
  • the invention provides an amorphous form of dapagliflozin. Although amorphous forms are sometimes better soluble than crystalline forms, they are often not the preferred form because of water activity and/or stability reasons. However, the present invention eliminates all aforesaid problems and bring additional advantages to the relevant prior art.
  • the main object of the present invention is to a solid pharmaceutical formulation comprising amorphous dapagliflozin which has the desired stability, dissolution profile, hardness and compressibility, in another words the disadvantages seen in the active substance in the art, is able to overcome.
  • Another object of the present invention is to eliminate problems and bringing additional advantages to the relevant prior art and problem of content uniformity which overcomes the above described problems in prior art.
  • the invention provides a solid pharmaceutical formulation comprising amorphous dapagliflozin.
  • the solid pharmaceutical formulation does not comprise described problems in prior art about active agent.
  • the formulation provides long shelf life and high stability during shelf life.
  • the solid pharmaceutical formulation comprising amorphous dapagliflozin provides the desired bioavailability.
  • a solid pharmaceutical formulation comprising amorphous dapagliflozin and at least one pharmaceutically acceptable excipient.
  • 'particle size means the cumulative volume size distrubition as tested by any conventionally accepted method such as the laser diffraction method (i.e. malvern analysis).
  • d (0.1) means, the size at which 10% by volume of the particles are finer and d (0.5) means the size at which 50% by volume of the particles are finer and d (0.9) means the size at which %90 by volume of the particles are finer.
  • dapagliflozin having the following particle sizes is very important for formulation. Especially, it positively affects the dissolution properties and powder homogenization.
  • the obtained tablets have the desired dissolution profile.
  • the powder is more homogeneous.
  • the content uniformity of the tablets obtained from the more homogeneous powder is more ideal. Therefore, it provides better bioavailability.
  • amorphous dapagliflozine has a d (0.9) particle size between 20 ⁇ m to 140 ⁇ m.
  • amorphous dapagliflozine has a d (0.9) particle size between 22 ⁇ m to 130 ⁇ m, between 25 ⁇ m to 120 ⁇ m, between 30 ⁇ m to 110 ⁇ m, between 35 ⁇ m to 100 ⁇ m, between 40 ⁇ m to 98 ⁇ m, between 45 ⁇ m to 95 ⁇ m, between 47 ⁇ m to 90 ⁇ m, between 50 ⁇ m to 85 ⁇ m.
  • amorphous dapagliflozine has a d (0.1) particle size between 3 ⁇ m to 60 ⁇ m.
  • amorphous dapagliflozine has a d (0.1) particle size between 5 ⁇ m to 55 ⁇ m, between 6 ⁇ m to 50 ⁇ m, between 7 ⁇ m to 45 ⁇ m, between 8 ⁇ m to 40 ⁇ m, between 9 ⁇ m to 30 ⁇ m.
  • amorphous dapagliflozine has a d (0.5) particle size between 8 ⁇ m to 90 ⁇ m.
  • amorphous dapagliflozine has a d (0.5) particle size between 9 ⁇ m to 85 ⁇ m, between 10 ⁇ m to 80 ⁇ m, between 11 ⁇ m to 75 ⁇ m, between 11 ⁇ m to 70 ⁇ m, between 15 ⁇ m to 60 ⁇ m, between 18 ⁇ m to 55 ⁇ m, between 20 ⁇ m to 50 ⁇ m, between 25 ⁇ m to 45 ⁇ m.
  • the amount of amorphous dapagliflozin is 0.05% to 8.0% by weight, preferably 0.05.% to 5.0% by weight in the total composition.
  • Dapagliflozin is used small proportion that can lead to considerable problems during the manufacture of the composition with regard to the uniformity of the content of active agent in the individual composition units. Because of problems uniformity of the content, the active substance may interact with several excipients. It reflects that content uniformity play important role in the dissolution of the drug. Using the right excipients is ensured uniformity of the content.
  • At least one pharmaceutically acceptable excipient is selected from fillers, binders, disintegrants, lubricants, glidants or mixtures thereof.
  • Suitable fillers are selected from the group comprising microcrystalline cellulose, anhydrous lactose, lactose, starch, mannitol, calcium hydrogen phosphate dihydrate, dicalcium hydrogen phosphate anhydrate, calcium phosphate trihydrate, silicon dioxide, neutral pellets, magnesium carbonate, magnesium oxide, maltodextrin, maltose, medium chain triglycerides or mixtures thereof.
  • the filler is microcrystalline cellulose or anhydrous lactose.
  • the amount of fillers is 5.0% to 92% by weight.
  • the amount of fillers is 5.0% to 40.0% or 58.0% to 92.0% by weight in the total composition.
  • Suitable binders are selected from the group comprising polyvinylpyrrolidone (povidone), hydroxypropylmethylcellulose, carboxymethylcellulose sodium, lactose anhydrous, pregelatinized starch, calcium carbonate, calcium phosphate dibasic, calcium phosphate tribasic, calcium sulphate, hydroxypropylcellulose, methyl cellulose, ethyl cellulose or mixtures thereof.
  • the binder is polyvinylpyrrolidone or hydroxypropylmethylcellulose or carboxymethylcellulose sodium.
  • the amount of binders is 0.5% to 15% by weight in the total composition. This amount of binders provides the desired dissolution profile.
  • Suitable disintegrants are selected from the group comprising croscarmellose sodium, crospovidone, sodium starch glycollate, sodium alginate, gums, starch and magnesium aluminum silicate or a mixture thereof.
  • the disintegrant is croscarmellose sodium or crospovidone.
  • the amount of disintegrants is 0.05% to 10.0% by weight, preferably 1.0% to 4.0% by weight in the total composition. This amount of disintegrants provides the desired dissolution profile.
  • Suitable glidant are selected from group comprising colloidal silicon dioxide, magnesium oxide, starch, magnesium silicate, colloidal silica or mixtures thereof.
  • the glidant is colloidal silicon dioxide.
  • the amount of glidants is 0.05% to 3.0% by weight in the total composition.
  • Suitable lubricants are selected from the group comprising magnesium stearate, sodium stearyl fumarate, silica colloidal anhydrous, talc, polyethylene glycol, stearic acid, aluminum silicate or mixtures thereof.
  • the lubricant is magnesium stearate or sodium stearyl fumarate.
  • the amount of lubricants is 0.01% to 5.0% by weight in the total composition.
  • modified release formulations in the solid pharmaceutical formulation, can be preferred.
  • Modified release formulations are selected from the group comprising controlled release, sustained release, delayed release, extended release, repeat action system or mixtures thereof.
  • formulation is prepared using matrix agents.
  • Suitable matrix agents are selected from the group comprising hydroxypropylmethyl cellulose, ethyl cellulose, polymethylmethacrylate derivatives's, poloxamer, polyvinyl alcohol, xanthan gum, sodium alginate, polymethacrylates, polyacrylamide, semi-synthetic polymers such as methyl cellulose, hydroxypropyl cellulose, polyvinyl acetate, cellulose acetate phthalate, ethylene vinyl acetate, methyl aminoethyl methacrylate, neutral methacrylic acid esters, polylactide, polylactide co-glycolide, low molecular weight polyethylene/polyisobutylene, polyanhydrides and poly (ortho-esters), diethyl aminoethyl methacrylate or mixtures thereof.
  • the amount of matrix agents is 10.0% to 30.0% by weight in the total composition.
  • the solid pharmaceutical formulation is in the form of film-coated tablet, bilayer tablet, multilayer tablet, orally disintegrating tablet, mini tablet, pellet, buccal tablet, sublingual tablet, effervescent tablet, capsule.
  • the solid pharmaceutical formulation is in the form of film-coated tablet which comprises at least one film coating agent.
  • Suitable film coating agents are selected from the group comprising polymethacrylates, hydroxypropyl methylcellulose, lactose monohydrate, talc, hydroxypropyl cellulose, polyvinyl alcohol (PVA), polyethylene glycol (PEG), talc, glycerin, polyvinyl alcohol-polyethylene glycol copolymers (Kollicoat ® IR), ethylcellulose dispersions (Surelease ® ), polyvinylprolidone, polyvinylprolidone-vinyl acetate copolymer (PVP-VA), iron oxide yellow, iron oxide, all kinds of Opadry ® , pigments, dyes, titanium dioxide, coloring agent or mixtures thereof.
  • the film coating agents are selected from the group comprising polyvinyl alcohol, talc, titanium dioxide, polyethylene glycol, iron oxide, iron oxide yellow.
  • the amount of film coating agents is 1.0% to 10.0% by weight, preferably 1.5 to 6.0% by weight in the total composition.
  • the solid pharmaceutical formulation is in the form of bilayer tablet or multilayer tablet.
  • amorphous dapagliflozin is present in a combination therapy.
  • combinations can be with at least one dipeptidyl peptidase-4 (DPP-4) inhibitor agent.
  • DPP-4 dipeptidyl peptidase-4
  • amorphous dapagliflozin and metformin hydrochloride amorphous dapagliflozin and saxagliptin in the form the free base or in the form of pharmaceutically acceptable salts
  • amorphous dapagliflozin and saxagliptin in the form the free base or in the form of pharmaceutically acceptable salts and metformin HCI amorphous dapagliflozin and sitagliptin in the form the free base or in the form of pharmaceutically acceptable salts.
  • amorphous dapagliflozin is present in a combination therapy which are with metformin HCl or saxagliptin in the form the free base or in the form of pharmaceutically acceptable salts or sitagliptin in the form the free base or in the form of pharmaceutically acceptable salts or mixtures thereof.
  • the solid pharmaceutical formulation of the present invention may be prepared, using standard techniques and manufacturing processes well known in the art, such as direct compression, wet granulation or dry granulation, hot melt granulation, hot melt extrusion, fluidized bed granulation, extrusion/spheronization, slugging, spray drying and solvent evaporation.
  • Example 1 The film coated tablet
  • Active ingredient and excipient Ingredients in one tablet (%) (by weight) Amorphous dapagliflozin 0.05 - 8.0 Microcrystalline cellulose 50.0 - 80.0 Anhydrous lactose 8.0 - 25.0 Crospovidone 1.0 - 10.0 Colloidal silicone dioxide 0.5 - 5.0 Magnesium stearate 0.5 - 5.0 Film coating agents 1.0 - 8.0 Total 100
  • Example 2 The film coated tablet
  • Active ingredient and excipient Ingredients in one tablet (%) (by weight) Amorphous dapagliflozin 3.8 Microcrystalline cellulose 66.8 Anhydrous lactose 19.2 Crospovidone 3.8 Colloidal silicone dioxide 1.5 Magnesium stearate 1.0 Film coating agents 3.8 Total 100
  • Example 3 The film coated tablet comprising amorphous dapagliflozin and metformin HCl
  • Active ingredient and excipient Ingredients in one tablet (%) (by weight) Amorphous dapagliflozin 0.05 - 5.0 Metformin HCl 55.0 - 80.0 Polyvinylpyrrolidone 2.0 - 15.0 Microcrystalline cellulose 5.0 - 30.0 Croscarmellose sodium 1.0 - 10.0 Magnesium stearate 0.1 -5.0 Film coating agents 2.0 - 10.0 Total 100
  • Example 4 The film coated tablet comprising amorphous dapagliflozin and metformin HCl
  • Active ingredient and excipient Ingredients in one tablet (%) (by weight) Amorphous dapagliflozin 0.3 Metformin HCI 68.5 Polyvinylpyrrolidone 5.5 Microcrystalline cellulose 16.8 Croscarmellose sodium 2.4 Magnesium stearate 1.0 Film coating agents 5.5 Total 100
  • Example 5 The bilayer tablet having extended release form comprising amorphous dapagliflozin and metformin HCl
  • the immediate release layer (first layer) Amorphous dapagliflozin 0.1 -8.0 Microcrystalline cellulose 5.0 - 30.0 Anhydrous lactose 1.0 - 10.0 Croscarmellose sodium 0.05 - 3.0 Colloidal silicon dioxide 0.05 - 3.0 Sodium stearyl fumarate 0.05 - 3.0
  • the extended release layer (second layer) Metformin HCI 40.0 - 80.0 At least one matrix agent (for example; hydroxypropyl methylcellulose (HPMC K100 MCR/K100/CN10T)) 10.0 - 30.0 Hydroxypropylmethyl cellulose as binder 0.1 - 6.0 Carboxymethylcellulose sodium 0.5 - 6.0 Magnesium stearate 0.01 - 3.0 Film-coating Film coating agents 1.0 - 8.0 Total of the weight of the bilayer tablet 100
  • Example 6 The bilayer tablet having extended release form comprising amorphous dapagliflozin and metformin HCl
  • Active ingredient and excipient Ingredients in one layer (%) (by weight)
  • the immediate release layer (first layer) Amorphous dapagliflozin 0.6 Microcrystalline cellulose 11.7 Anhydrous lactose 2.9 Croscarmellose sodium 0.9 Colloidal silicon dioxide 0.3 Sodium stearyl fumarate 0.4
  • the extended release layer (second layer) Metformin HCI 59.9 At least one matrix agent 16.4 Hydroxypropylmethylcellulose as binder 1.2 Carboxymethylcellulose Sodium 3.0 Magnesium stearate 0.4 Film-coating Film coating agents 2.4 Total of the weight of the bilayer tablet 100

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to a solid pharmaceutical formulation comprising amorphous dapagliflozin and at least one pharmaceutically acceptable excipient. Further, the formulations comprising amorphous dapagliflozin are prepared a method which is simple, rapid, cost effective, time-saving and industrially convenient process.

Description

    Field of the Invention
  • The present invention relates to a solid pharmaceutical formulation comprising amorphous dapagliflozin and at least one pharmaceutically acceptable excipient. Further, the formulations comprising amorphous dapagliflozin are prepared a method which is simple, rapid, cost effective, time-saving and industrially convenient process.
    • Background of the Invention
  • Diabetes mellitus is a group of disorders of carbohydrate metabolism in which the action of insulin is diminished or absent through altered secretion, decreased insulin activity or a combination of both factors. There are two main types of diabetes; Type 1 and Type 2:
    Type 1 diabetes occurs because the insulin-producing cells of the pancreas (beta cells) are damaged. In Type 1 diabetes, the pancreas makes little or no insulin, so sugar cannot get into the body's cells for use as energy. People with Type 1 diabetes must use insulin injections to control their blood glucose.
  • In Type 2 diabetes, the pancreas makes insulin, but it either doesn't produce enough, or the insulin does not work properly. This diabetes occurs most often in people who are over 40 years old and overweight and type 2 diabetes is the most common type, affecting more than 171 million people worldwide.Type 2 diabetes may sometimes be controlled with a combination of diet, weight management, and exercise. However, treatment also may include oral glucose-lowering medications or insulin injections.
  • Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor (SGLT2). SGLT2 is a carrier responsible for the reabsorption of most of the glucose from the lumen of the renal tubule. SGLT2 is expressed in proximal renal tubules. By inhibiting SGLT2, dapagliflozin reduces the reabsorption of the filtered glucose and lowers the renal threshold for glucose. This improves urinary glucose excretion and blood glucose control. Dapagliflozin, also known as (1S)-1,5-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-D-glucitol or (2S,3R,4R,5S,6R)-2-(3-(4-etoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol is represented by the structure of Formula I.
    Figure imgb0001
  • Dapagliflozin was first disclosed in patent US 6515117 (2003, Bristol-Myers Squibb ).
  • US2008234366 A1 , US2011064801 A1 and US2012263786 A1 disclose pharmaceutical compositions comprising dapagliflozin or dapagliflozin propylene glycol hydrate and specific excipients in given amounts.
  • WO2008116178 refers to pharmaceutical formulations which include crystalline dapagliflozin propylene glycol hydrate.
  • US2011064801 A1 further discloses pharmaceutical compositions in the form of a stock granulation comprising dapagliflozin propylene glycol hydrate and excipients in given amounts.
  • Although several solid forms comprising dapagliflozin are known in the art, finding a good or even the optimal form with regard to bioavailability and safety remains a considerable challenge, in particular when the compound forms many polymorphic forms. Not all solid forms comprising dapagliflozin are equally suitable with regard to stability, flow properties, compressibility, dissolution rate.
  • In view of the above art, there is still a need for an effective solid pharmaceutical formulation comprising of a form of dapagliflozin. The invention provides an amorphous form of dapagliflozin. Although amorphous forms are sometimes better soluble than crystalline forms, they are often not the preferred form because of water activity and/or stability reasons. However, the present invention eliminates all aforesaid problems and bring additional advantages to the relevant prior art.
    • Detailed Description of the Invention
  • The main object of the present invention is to a solid pharmaceutical formulation comprising amorphous dapagliflozin which has the desired stability, dissolution profile, hardness and compressibility, in another words the disadvantages seen in the active substance in the art, is able to overcome.
  • Another object of the present invention is to eliminate problems and bringing additional advantages to the relevant prior art and problem of content uniformity which overcomes the above described problems in prior art.
  • The invention provides a solid pharmaceutical formulation comprising amorphous dapagliflozin. The solid pharmaceutical formulation does not comprise described problems in prior art about active agent. The formulation provides long shelf life and high stability during shelf life. Also, the solid pharmaceutical formulation comprising amorphous dapagliflozin provides the desired bioavailability.
  • According to an embodiment of the present invention, a solid pharmaceutical formulation comprising amorphous dapagliflozin and at least one pharmaceutically acceptable excipient.
  • As used here in, 'particle size' means the cumulative volume size distrubition as tested by any conventionally accepted method such as the laser diffraction method (i.e. malvern analysis). The term d (0.1) means, the size at which 10% by volume of the particles are finer and d (0.5) means the size at which 50% by volume of the particles are finer and d (0.9) means the size at which %90 by volume of the particles are finer.
  • We have found that dapagliflozin having the following particle sizes is very important for formulation. Especially, it positively affects the dissolution properties and powder homogenization. The obtained tablets have the desired dissolution profile. The powder is more homogeneous. The content uniformity of the tablets obtained from the more homogeneous powder is more ideal. Therefore, it provides better bioavailability.
  • According to an embodiment of the present invention, amorphous dapagliflozine has a d (0.9) particle size between 20 µm to 140 µm.
  • According to an embodiment of the present invention, amorphous dapagliflozine has a d (0.9) particle size between 22 µm to 130 µm, between 25 µm to 120 µm, between 30 µm to 110 µm, between 35 µm to 100 µm, between 40 µm to 98 µm, between 45 µm to 95 µm, between 47 µm to 90 µm, between 50 µm to 85 µm.
  • According to an embodiment of the present invention, amorphous dapagliflozine has a d (0.1) particle size between 3 µm to 60 µm.
  • According to an embodiment of the present invention, amorphous dapagliflozine has a d (0.1) particle size between 5 µm to 55 µm, between 6 µm to 50 µm, between 7 µm to 45 µm, between 8 µm to 40 µm, between 9 µm to 30 µm.
  • According to an embodiment of the present invention, amorphous dapagliflozine has a d (0.5) particle size between 8 µm to 90 µm.
  • According to an embodiment of the present invention, amorphous dapagliflozine has a d (0.5) particle size between 9 µm to 85 µm, between 10 µm to 80 µm, between 11 µm to 75 µm, between 11 µm to 70 µm, between 15 µm to 60 µm, between 18 µm to 55 µm, between 20 µm to 50 µm, between 25 µm to 45 µm.
  • According to an embodiment of the present invention, the amount of amorphous dapagliflozin is 0.05% to 8.0% by weight, preferably 0.05.% to 5.0% by weight in the total composition.
  • Dapagliflozin is used small proportion that can lead to considerable problems during the manufacture of the composition with regard to the uniformity of the content of active agent in the individual composition units. Because of problems uniformity of the content, the active substance may interact with several excipients. It reflects that content uniformity play important role in the dissolution of the drug. Using the right excipients is ensured uniformity of the content.
  • According to an embodiment of the present invention, at least one pharmaceutically acceptable excipient is selected from fillers, binders, disintegrants, lubricants, glidants or mixtures thereof.
  • Suitable fillers are selected from the group comprising microcrystalline cellulose, anhydrous lactose, lactose, starch, mannitol, calcium hydrogen phosphate dihydrate, dicalcium hydrogen phosphate anhydrate, calcium phosphate trihydrate, silicon dioxide, neutral pellets, magnesium carbonate, magnesium oxide, maltodextrin, maltose, medium chain triglycerides or mixtures thereof.
  • According to an embodiment of the present invention, the filler is microcrystalline cellulose or anhydrous lactose.
  • According to an embodiment of the present invention, the amount of fillers is 5.0% to 92% by weight.
  • According to an embodiment of the present invention, the amount of fillers is 5.0% to 40.0% or 58.0% to 92.0% by weight in the total composition.
  • Suitable binders are selected from the group comprising polyvinylpyrrolidone (povidone), hydroxypropylmethylcellulose, carboxymethylcellulose sodium, lactose anhydrous, pregelatinized starch, calcium carbonate, calcium phosphate dibasic, calcium phosphate tribasic, calcium sulphate, hydroxypropylcellulose, methyl cellulose, ethyl cellulose or mixtures thereof.
  • According to an embodiment of the present invention, the binder is polyvinylpyrrolidone or hydroxypropylmethylcellulose or carboxymethylcellulose sodium.
  • According to an embodiment of the present invention, the amount of binders is 0.5% to 15% by weight in the total composition. This amount of binders provides the desired dissolution profile.
  • Suitable disintegrants are selected from the group comprising croscarmellose sodium, crospovidone, sodium starch glycollate, sodium alginate, gums, starch and magnesium aluminum silicate or a mixture thereof.
  • According to an embodiment of the present invention, the disintegrant is croscarmellose sodium or crospovidone.
  • According to an embodiment of the present invention, the amount of disintegrants is 0.05% to 10.0% by weight, preferably 1.0% to 4.0% by weight in the total composition. This amount of disintegrants provides the desired dissolution profile.
  • Suitable glidant are selected from group comprising colloidal silicon dioxide, magnesium oxide, starch, magnesium silicate, colloidal silica or mixtures thereof.
  • According to an embodiment of the present invention, the glidant is colloidal silicon dioxide.
  • According to an embodiment of the present invention, the amount of glidants is 0.05% to 3.0% by weight in the total composition.
  • Suitable lubricants are selected from the group comprising magnesium stearate, sodium stearyl fumarate, silica colloidal anhydrous, talc, polyethylene glycol, stearic acid, aluminum silicate or mixtures thereof.
  • According to an embodiment of the present invention, the lubricant is magnesium stearate or sodium stearyl fumarate.
  • According to an embodiment of the present invention, the amount of lubricants is 0.01% to 5.0% by weight in the total composition.
  • According to an embodiment of the present invention, in the solid pharmaceutical formulation, modified release formulations can be preferred. Modified release formulations are selected from the group comprising controlled release, sustained release, delayed release, extended release, repeat action system or mixtures thereof. At this invention, formulation is prepared using matrix agents.
  • Suitable matrix agents are selected from the group comprising hydroxypropylmethyl cellulose, ethyl cellulose, polymethylmethacrylate derivatives's, poloxamer, polyvinyl alcohol, xanthan gum, sodium alginate, polymethacrylates, polyacrylamide, semi-synthetic polymers such as methyl cellulose, hydroxypropyl cellulose, polyvinyl acetate, cellulose acetate phthalate, ethylene vinyl acetate, methyl aminoethyl methacrylate, neutral methacrylic acid esters, polylactide, polylactide co-glycolide, low molecular weight polyethylene/polyisobutylene, polyanhydrides and poly (ortho-esters), diethyl aminoethyl methacrylate or mixtures thereof. The amount of matrix agents is 10.0% to 30.0% by weight in the total composition.
  • According to an embodiment of the present invention, the solid pharmaceutical formulation is in the form of film-coated tablet, bilayer tablet, multilayer tablet, orally disintegrating tablet, mini tablet, pellet, buccal tablet, sublingual tablet, effervescent tablet, capsule.
  • According to an embodiment of the present invention, the solid pharmaceutical formulation is in the form of film-coated tablet which comprises at least one film coating agent.
  • Suitable film coating agents are selected from the group comprising polymethacrylates, hydroxypropyl methylcellulose, lactose monohydrate, talc, hydroxypropyl cellulose, polyvinyl alcohol (PVA), polyethylene glycol (PEG), talc, glycerin, polyvinyl alcohol-polyethylene glycol copolymers (Kollicoat® IR), ethylcellulose dispersions (Surelease®), polyvinylprolidone, polyvinylprolidone-vinyl acetate copolymer (PVP-VA), iron oxide yellow, iron oxide, all kinds of Opadry®, pigments, dyes, titanium dioxide, coloring agent or mixtures thereof.
  • According to an embodiment of the present invention, the film coating agents are selected from the group comprising polyvinyl alcohol, talc, titanium dioxide, polyethylene glycol, iron oxide, iron oxide yellow.
  • According to an embodiment of the present invention, the amount of film coating agents is 1.0% to 10.0% by weight, preferably 1.5 to 6.0% by weight in the total composition.
  • According to an embodiment of the present invention, the solid pharmaceutical formulation is in the form of bilayer tablet or multilayer tablet.
  • According to an embodiment of the present invention, amorphous dapagliflozin is present in a combination therapy. Especially; combinations can be with at least one dipeptidyl peptidase-4 (DPP-4) inhibitor agent. For example; amorphous dapagliflozin and metformin hydrochloride, amorphous dapagliflozin and saxagliptin in the form the free base or in the form of pharmaceutically acceptable salts, amorphous dapagliflozin and saxagliptin in the form the free base or in the form of pharmaceutically acceptable salts and metformin HCI, amorphous dapagliflozin and sitagliptin in the form the free base or in the form of pharmaceutically acceptable salts.
  • According to an embodiment of the present invention, amorphous dapagliflozin is present in a combination therapy which are with metformin HCl or saxagliptin in the form the free base or in the form of pharmaceutically acceptable salts or sitagliptin in the form the free base or in the form of pharmaceutically acceptable salts or mixtures thereof.
  • The solid pharmaceutical formulation of the present invention may be prepared, using standard techniques and manufacturing processes well known in the art, such as direct compression, wet granulation or dry granulation, hot melt granulation, hot melt extrusion, fluidized bed granulation, extrusion/spheronization, slugging, spray drying and solvent evaporation.
    • Example 1: The film coated tablet
  • Active ingredient and excipient Ingredients in one tablet (%) (by weight)
    Amorphous dapagliflozin 0.05 - 8.0
    Microcrystalline cellulose 50.0 - 80.0
    Anhydrous lactose 8.0 - 25.0
    Crospovidone 1.0 - 10.0
    Colloidal silicone dioxide 0.5 - 5.0
    Magnesium stearate 0.5 - 5.0
    Film coating agents 1.0 - 8.0
    Total 100
    • Example 2: The film coated tablet
  • Active ingredient and excipient Ingredients in one tablet (%) (by weight)
    Amorphous dapagliflozin 3.8
    Microcrystalline cellulose 66.8
    Anhydrous lactose 19.2
    Crospovidone 3.8
    Colloidal silicone dioxide 1.5
    Magnesium stearate 1.0
    Film coating agents 3.8
    Total 100
    • A process for example 1 or 2;
    1. a) Mixing amorphous dapagliflozin, microcrystalline cellulose, anhydrous lactose, crospovidone and colloidal silicone dioxide,
    2. b) Adding magnesium stearate and then mixing,
    3. c) Compressing the mixture to form of tablet,
    4. d) Coating tablets with film coating agents.
    Example 3: The film coated tablet comprising amorphous dapagliflozin and metformin HCl
  • Active ingredient and excipient Ingredients in one tablet (%) (by weight)
    Amorphous dapagliflozin 0.05 - 5.0
    Metformin HCl 55.0 - 80.0
    Polyvinylpyrrolidone 2.0 - 15.0
    Microcrystalline cellulose 5.0 - 30.0
    Croscarmellose sodium 1.0 - 10.0
    Magnesium stearate 0.1 -5.0
    Film coating agents 2.0 - 10.0
    Total 100
    • Example 4: The film coated tablet comprising amorphous dapagliflozin and metformin HCl
  • Active ingredient and excipient Ingredients in one tablet (%) (by weight)
    Amorphous dapagliflozin 0.3
    Metformin HCI 68.5
    Polyvinylpyrrolidone 5.5
    Microcrystalline cellulose 16.8
    Croscarmellose sodium 2.4
    Magnesium stearate 1.0
    Film coating agents 5.5
    Total 100
    • A process for example 3 or 4;
    1. a) Mixing amorphous dapagliflozin, metformin HC, croscarmellose sodium, microcrystalline cellulose,
    2. b) Dissolving polyvinylpyrrolidone in pure water to obtained a solution,
    3. c) Spraying the solution with the mixture at step (a).
    4. d) Drying the mixture, then sieving the mixture,
    5. e) Adding magnesium stearate and then mixing,
    6. f) Compressing the mixture to form of tablet,
    7. g) Coating tablets with film coating agents.
    Example 5: The bilayer tablet having extended release form comprising amorphous dapagliflozin and metformin HCl
  • Active ingredient and excipient Ingredients in one layer (%) (by weight)
    The immediate release layer (first layer)
    Amorphous dapagliflozin 0.1 -8.0
    Microcrystalline cellulose 5.0 - 30.0
    Anhydrous lactose 1.0 - 10.0
    Croscarmellose sodium 0.05 - 3.0
    Colloidal silicon dioxide 0.05 - 3.0
    Sodium stearyl fumarate 0.05 - 3.0
    The extended release layer (second layer)
    Metformin HCI 40.0 - 80.0
    At least one matrix agent (for example; hydroxypropyl methylcellulose (HPMC K100 MCR/K100/CN10T)) 10.0 - 30.0
    Hydroxypropylmethyl cellulose as binder 0.1 - 6.0
    Carboxymethylcellulose sodium 0.5 - 6.0
    Magnesium stearate 0.01 - 3.0
    Film-coating
    Film coating agents 1.0 - 8.0
    Total of the weight of the bilayer tablet 100
    • Example 6: The bilayer tablet having extended release form comprising amorphous dapagliflozin and metformin HCl
  • Active ingredient and excipient Ingredients in one layer (%) (by weight)
    The immediate release layer (first layer)
    Amorphous dapagliflozin 0.6
    Microcrystalline cellulose 11.7
    Anhydrous lactose 2.9
    Croscarmellose sodium 0.9
    Colloidal silicon dioxide 0.3
    Sodium stearyl fumarate 0.4
    The extended release layer (second layer)
    Metformin HCI 59.9
    At least one matrix agent 16.4
    Hydroxypropylmethylcellulose as binder 1.2
    Carboxymethylcellulose Sodium 3.0
    Magnesium stearate 0.4
    Film-coating
    Film coating agents 2.4
    Total of the weight of the bilayer tablet 100
    • A process for example 5 or 6;
    1. 1. The immediate release layer
      1. a. Mixing amorphous dapagliflozin and colloidal silicon dioxide,
      2. b. Adding anhydrous lactose and croscarmellose sodium,
      3. c. Adding microcrystalline cellulose and then mixing,
      4. d. Adding sodium stearyl fumarate and then mixing,
    2. 2. The extended release layer
      1. a. Mixing metformin HCI, carboxymethylcellulose sodium, hydroxypropyl methylcellulose
      2. b. Spraying the mixture with pure water,
      3. c. Drying the mixture, then sieving the mixture,
      4. d. Adding hydroxypropylmethylcellulose (HPMC K100 MCR/K100/CN10T) and then mixing,
      5. e. Adding magnesium stearate and then mixing,
    3. 3. Compressing the immediate release layer and extended release layer to form of a bilayer tablet,
    4. 4. Coating bilayer tablets with film coating agents.

Claims (15)

  1. A solid pharmaceutical formulation comprising amorphous dapagliflozin and at least one pharmaceutically acceptable excipient.
  2. The solid pharmaceutical formulation according to claim 1, wherein amorphous dapagliflozine has a d (0.9) particle size between 20 µm to 140 µm.
  3. The solid pharmaceutical formulation according to claim 1, wherein amorphous dapagliflozine has a d (0.1) particle size between 3 µm to 60 µm.
  4. The solid pharmaceutical formulation according to claim 1, wherein amorphous dapagliflozine has a d (0.5) particle size between 8 µm to 90 µm.
  5. The solid pharmaceutical formulation according to claim 1, wherein the amount of amorphous dapagliflozin is 0.05% to 8.0% by weight, preferably 0.05.% to 5.0% by weight in the total composition.
  6. The solid pharmaceutical formulation according to claim 1, wherein at least one pharmaceutically acceptable excipient is selected from fillers, binders, disintegrants, lubricants, glidants or mixtures thereof.
  7. The solid pharmaceutical formulation according to claim 6, wherein fillers are selected from the group comprising microcrystalline cellulose, anhydrous lactose, lactose, starch, mannitol, calcium hydrogen phosphate dihydrate, dicalcium hydrogen phosphate anhydrate, calcium phosphate trihydrate, silicon dioxide, neutral pellets, magnesium carbonate, magnesium oxide, maltodextrin, maltose, medium chain triglycerides or mixtures thereof.
  8. The solid pharmaceutical formulation according to claim 6, wherein binders are selected from the group comprising polyvinylpyrrolidone (povidone), hydroxypropylmethylcellulose, carboxymethylcellulose sodium, lactose anhydrous, pregelatinized starch, calcium carbonate, calcium phosphate dibasic, calcium phosphate tribasic, calcium sulphate, hydroxypropylcellulose, methyl cellulose, ethyl cellulose or mixtures thereof.
  9. The solid pharmaceutical formulation according to claim 8, wherein the amount of binders is 0.5% to 15% by weight in the total composition.
  10. The solid pharmaceutical formulation according to claim 6, wherein disintegrants are selected from the group comprising croscarmellose sodium, crospovidone, sodium starch glycollate, sodium alginate, gums, starch and magnesium aluminum silicate or a mixture thereof.
  11. The solid pharmaceutical formulation according to claim 10, wherein the amount of disintegrants is 0.05% to 10.0% by weight in the total composition.
  12. The solid pharmaceutical formulation according to claim 6, wherein glidant are selected from group comprising colloidal silicon dioxide, magnesium oxide, starch, magnesium silicate, colloidal silica or mixtures thereof.
  13. The solid pharmaceutical formulation according to claim 6, wherein lubricants are selected from the group comprising magnesium stearate, sodium stearyl fumarate, silica colloidal anhydrous, talc, polyethylene glycol, stearic acid, aluminum silicate or mixtures thereof.
  14. The solid pharmaceutical formulation according to claim 1, wherein the formulation is in the form of film-coated tablet, bilayer tablet, multilayer tablet, orally disintegrating tablet, mini tablet, pellet, buccal tablet, sublingual tablet, effervescent tablet, immediate release tablet, modified release tablet, capsule.
  15. The solid pharmaceutical formulation according to claim 1, wherein amorphous dapagliflozin is present in a combination therapy which are with metformin HCI or saxagliptin in the form the free base or in the form of pharmaceutically acceptable salts or sitagliptin in the form the free base or in the form of pharmaceutically acceptable salts or mixtures thereof.
EP21211906.9A 2020-12-03 2021-12-02 Solid pharmaceutical formulations of amorphous dapagliflozin Pending EP4008317A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2020/19592A TR202019592A2 (en) 2020-12-03 2020-12-03 Solid pharmaceutical formulations of amorphous dapagliflozin

Publications (1)

Publication Number Publication Date
EP4008317A1 true EP4008317A1 (en) 2022-06-08

Family

ID=78821016

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21211906.9A Pending EP4008317A1 (en) 2020-12-03 2021-12-02 Solid pharmaceutical formulations of amorphous dapagliflozin

Country Status (3)

Country Link
EP (1) EP4008317A1 (en)
TR (2) TR202019592A2 (en)
WO (1) WO2022119542A1 (en)

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
WO2008116178A2 (en) 2007-03-21 2008-09-25 Vanderbilt University Systems and methods for diagnosis and prognosis of colorectal cancer
US20080234366A1 (en) 2007-03-22 2008-09-25 Bristol-Myers Squibb Pharmaceutical formulation containing an sglt2 inhibitor
WO2015128853A1 (en) * 2014-02-28 2015-09-03 Sun Pharmaceutical Industries Limited Dapagliflozin compositions
WO2016161995A1 (en) * 2015-04-08 2016-10-13 Zentiva, K.S. Solid forms of amorphous dapagliflozin
US20170166547A1 (en) * 2015-10-19 2017-06-15 Cadila Healthcare Limited Process for the preparation of dapagliflozin
IN201621005029A (en) 2016-02-12 2017-11-24 Torrent Pharmaceuticals Ltd
WO2017203229A1 (en) * 2016-05-27 2017-11-30 Cipla Limited Dapagliflozin premixes
IN201641042600A (en) 2016-12-14 2018-06-15 Msn Laboratories Private Ltd
WO2018167589A1 (en) * 2017-03-16 2018-09-20 Inventia Healthcare Private Limited Pharmaceutical composition comprising dapagliflozin
WO2021086292A1 (en) * 2019-10-31 2021-05-06 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Bilayer tablet formulations comprising dapagliflozin and metformin
WO2021165316A1 (en) * 2020-02-21 2021-08-26 Zakłady Farmaceutyczne POLPHARMA S.A. Pharmaceutical composition comprising dapagliflozin

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2721059T3 (en) * 2013-07-22 2019-07-26 Sandoz Ag Formulations containing amorphous dapagliflozin

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
WO2008116178A2 (en) 2007-03-21 2008-09-25 Vanderbilt University Systems and methods for diagnosis and prognosis of colorectal cancer
US20080234366A1 (en) 2007-03-22 2008-09-25 Bristol-Myers Squibb Pharmaceutical formulation containing an sglt2 inhibitor
US20110064801A1 (en) 2007-03-22 2011-03-17 Bristol-Myers Squibb Company Pharmaceutical Formulations Containing an SGLT2 Inhibitor
US20120263786A1 (en) 2007-03-22 2012-10-18 Bristol-Myers Squibb Company Pharmaceutical Formulations Containing an SGLT2 Inhibitor
WO2015128853A1 (en) * 2014-02-28 2015-09-03 Sun Pharmaceutical Industries Limited Dapagliflozin compositions
WO2016161995A1 (en) * 2015-04-08 2016-10-13 Zentiva, K.S. Solid forms of amorphous dapagliflozin
US20170166547A1 (en) * 2015-10-19 2017-06-15 Cadila Healthcare Limited Process for the preparation of dapagliflozin
IN201621005029A (en) 2016-02-12 2017-11-24 Torrent Pharmaceuticals Ltd
WO2017203229A1 (en) * 2016-05-27 2017-11-30 Cipla Limited Dapagliflozin premixes
IN201641042600A (en) 2016-12-14 2018-06-15 Msn Laboratories Private Ltd
WO2018167589A1 (en) * 2017-03-16 2018-09-20 Inventia Healthcare Private Limited Pharmaceutical composition comprising dapagliflozin
US11020412B2 (en) 2017-03-16 2021-06-01 Inventia Healthcare Limited Pharmaceutical composition comprising dapagliflozin
WO2021086292A1 (en) * 2019-10-31 2021-05-06 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Bilayer tablet formulations comprising dapagliflozin and metformin
WO2021165316A1 (en) * 2020-02-21 2021-08-26 Zakłady Farmaceutyczne POLPHARMA S.A. Pharmaceutical composition comprising dapagliflozin

Also Published As

Publication number Publication date
TR2021009380A2 (en) 2022-06-21
TR202019592A2 (en) 2022-06-21
WO2022119542A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
RU2423975C2 (en) Solid medication of olmesartan medoxomil and amlodipine
US20050266080A1 (en) Coated tablet formulation and method
US6696496B2 (en) Low water-soluble venlafaxine salts
EP3034071A1 (en) New combination
EP2468268B1 (en) Combination composition of vildagliptin and gliclazide
EP3976014A1 (en) A combination comprising alogliptin and metformin
WO2019194773A2 (en) The combination comprising linagliptin and metformin
US20150283248A1 (en) Pharmaceutical compositions of Linagliptin and process for preparation thereof
EP2638898A1 (en) Metformin and Pioglitazone Formulation with Different Release Profiles
EP3025707A1 (en) A multilayer tablet comprising metformin and pioglitazone
EP2839829B1 (en) Sustained release tablet containing levodropropizine and method for preparing same
EP4008317A1 (en) Solid pharmaceutical formulations of amorphous dapagliflozin
WO2021246985A1 (en) The process for the preparation of a film coated tablet comprising linagliptin and metformin
WO2019132833A1 (en) The modified release combination comprising linagliptin and metformin
EP4008316A1 (en) A film coated tablet formulation comprising dapagliflozin and metformin hydrochloride
EP4079296A1 (en) A bilayer tablet formulation comprising amorphous dapagliflozin and metformin
EP4212150A1 (en) A bilayer tablet composition comprising amorphous dapagliflozin and metformin
EP4008318A1 (en) A process for tablet formulations comprising amorphous dapagliflozin and metformin hydrochloride
EP4008315A1 (en) A process for formulations of dapagliflozin and metformin hydrochloride
EP4043009A1 (en) A process for formulations of linagliptin or a pharmaceutically acceptable salt thereof
WO2023136797A2 (en) A bilayer tablet composition comprising amorphous dapagliflozin and metformin
EP4378455A1 (en) A pharmaceutical formulation comprising empagliflozin
WO2023129050A1 (en) A pharmaceutical composition of empagliflozin and linagliptin processed with hot-melt extrusion
KR20220140343A (en) Oral composite formulation comprising evogliptin and metformin and method for preparing the same
EP4299055A1 (en) Oral dosage formulations comprising empagliflozin

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221207

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230708

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

17Q First examination report despatched

Effective date: 20240112